Office in Russia. Received revenues in Russia in 2022-2024. Dr Reddy’s Laboratories Ltd has infused ₹565.4 crore into its Russian arm, Dr Reddy’s Laboratories LLC (DRL Russia), acquiring a 45.19% equity stake in the step-down wholly-owned subsidiary. The investment, made on July 25, 2025, follows board approval granted on November 5, 2024, to inject up to ₹600 crore into the Russian entity. The capital was infused via cash and will be used to support DRL Russia’s working capital requirements. DRL Russia, which operates as a pharmaceutical distribution company in the Russian Federation, reported a turnover of ₹2,347 crore in FY25. Russia's R-Pharm and India's Dr. Reddy's will bring the cancer treatment drug toripalimab to the Russian market. Under the agreement between the companies, production of the finished dosage form will be localized at R-Pharm's facilities. Registration of the drug in Russia is expected in 2027.